Therapeutic proteins provide interventions for some of the most complex and intractable
diseases and are an essential part of modern medicine. Immunogenicity is the development …

The development of anti-drug antibodies (ADAs) following administration of biotherapeutics
to patients is a vexing problem that is attracting increasing attention from pharmaceutical …

Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Anti‐drug antibody formation following factor VIII (FVIII) replacement therapy is the most
important treatment‐related complication in patients with severe haemophilia A. A significant …

Immunogenicity is an important consideration in the licensure of a therapeutic protein
because the development of neutralizing anti-drug antibodies (ADAs) can affect both safety …

Major histocompatibility complex (MHC)-Associated Peptide Proteomics (MAPPs) is an ex
vivo method used to assess the immunogenicity risk of biotherapeutics. MAPPs can identify …

Abstract African American hemophilia A (HA) patients experience a higher incidence of
neutralizing anti-factor VIII (FVIII) antibodies (“inhibitors”) vis-à-vis white patients …

The development of neutralizing anti-FVIII antibodies (inhibitors) is a major complication of
FVIII protein replacement therapy in patients with hemophilia A (HA). Although multiple lines …

It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by
reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of …

Immunogenicity is a key factor capable of influencing the efficacy and safety of therapeutic
antibodies. A recently developed method called MHC-associated peptide proteomics …